OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer

Core Insights - OSE Immunotherapeutics provided clinical updates on its neo-epitope-based cancer vaccine Tedopi® for pancreatic cancer and non-small cell lung cancer (NSCLC) at the ASCO Annual Meeting, highlighting promising results in ongoing trials [2][3][8]. Company Overview - OSE Immunotherapeutics is a biotech company focused on developing innovative immuno-oncology and immuno-inflammation therapies to meet unmet patient needs [13]. - The company is based in Nantes and Paris and is listed on Euronext [13]. Clinical Trial Updates - The TEDOPaM trial, a Phase 2 study, demonstrated a 12-month overall survival (OS) rate of 65% in patients receiving Tedopi® combined with FOLFIRI chemotherapy, meeting its primary endpoint [6][14]. - The trial enrolled 107 patients, with a median follow-up of 21 months, and reported minimal toxicity associated with Tedopi® [6][14]. - Two complete responses were observed in the experimental arm, while no complete responses were noted in the control arm [14]. Pancreatic Cancer Insights - Pancreatic cancer is a highly aggressive disease, with a five-year survival rate of only 10% globally, and it is projected that new cases will increase by 95.4% by 2050 [10]. - Surgical resection is only feasible for 15-20% of patients at diagnosis, emphasizing the need for effective systemic therapies [11]. NSCLC Developments - The ARTEMIA Phase 3 trial is ongoing, aiming to evaluate Tedopi® as a second-line treatment for HLA-A2 positive NSCLC patients with secondary resistance to anti-PD-(L)1 immunotherapy [9]. - The trial is being conducted across 14 countries and aims to enroll 363 patients [9].